Pharmafile Logo

Inizio launches Intelligent Congress: Turning medical event investment into measurable impact

May 12, 2026 |  

Inizio, the global commercialization partner to the health and life sciences industry, today announced the launch of Intelligent Congress – a connected, end-to-end solution designed to help pharma organizations maximize the value of congress investment and deliver measurable business impact.

- PMLiVE

Medical congresses remain one of the most critical data milestones in an asset’s development, providing valuable opportunities to translate scientific innovation into clinical practice. However, many organizations still approach congresses as standalone events, with fragmented planning across therapy area teams, limited alignment to overarching disease area objectives, and limited clarity on measuring success beyond immediate metrics. 

By operating as a single, integrated partner across the full data and congress lifecycle, Inizio helps clients navigate complexity, align stakeholders, and gain clearer confidence in the impact of their congress investments. Our strength lies in an unmatched vantage point – combining deep, cross-functional expertise with end-to-end visibility across the product lifecycle. 

Intelligent Congress is built on this foundation. Drawing on more than 30 years of experience across therapy areas, it unites strategy, experience design, delivery, and measurement into one cohesive model. This depth and breadth enable clients to move beyond fragmented, activity-based metrics and instead focus on what truly matters – meaningful shifts in HCP understanding, engagement, and behavior. 

Discover how Intelligent Congress can help you create more strategic, measurable, and impactful HCP engagement. Visit our congress page or connect with the Inizio team at booth 21157 during the ASCO® Annual Meeting 2026 to see Intelligent Congress in action. 

Read full article here.

This content was provided by Inizio

Company Details

 Latest Content from  Inizio 

Infographic

Migraine market snapshot

Webcast

Monitoring the impact of COVID-19 on the market access landscape

Live webinar from Singapore

Digital #marcomms: How to evaluate and optimise marketing activities impacted by COVID-19

Guide

UX research

Article: Why pharma must trust the science of behaviour

In a recent interview with PME Magazine, Dan Coffin, Director explains why the application of behavioural science will be key to better health far beyond COVID-19.Read the full article here:...

Case study

Using qualitative conjoint to assess willingness-to-pay

Consumer health specialist joins Research Partnership Inc

Global healthcare market research consultancy Research Partnership has appointed Jennifer Stewart as a Director in their US offices in Philadelphia.

Article: What’s next? How behavioural science can support pharma’s future

Dan Coffin, Director explains why now is an opportune time for pharma marketers to embrace behavioural science. Read his latest article for PME Magazine.https://bit.ly/31ef6rh

Video: UX/ Experience design research

Director and UX expert Liza Pliss discusses Research Partnership's approach to user experience research and shares an example of a project where using design thinking led to an agile approach...

White paper: The impact of COVID-19 on chronic disease management

Therapy Watch, Research Partnership's syndicated PRF tracker, has been investigating the impact of COVID-19 on chronic disease management. In this white paper, Research Partnership share some of the insights and...